The global small molecule innovator CDMO market size was valued at USD 41.1 billion in 2020, and is predicted to be worth around USD 73.9 billion by 2030, registering a CAGR of 6.4% during the forecast period 2022 to 2030.
The global small molecule innovator CDMO market size was valued at USD 41.1 billion in 2020, and is predicted to be worth around USD 73.9 billion by 2030, registering a CAGR of 6.4% during the forecast period 2022 to 2030.
Growth Factors
The COVID-19 pandemic has significantly impacted market growth. During this crisis, CDMOs are playing an important role in meeting the needs of pharmaceutical companies, biotech companies, and other end users. These have been working diligently towards the development of small-molecule drugs against SARS-CoV-2 since the end of 2019.
COVID-19 has caused a significant impact on the API CDMO market where China was a key performing country in contract manufacturing of APIs. In China, due to a strict government-imposed lockdown, 44 firms became non-operational and several governments chose to boycott APIs manufactured in China. To combat this shortage, several countries have started manufacturing their own APIs. COVID-19 has changed supply chains but has also boosted the API CDMO market. With the growing demand for outsourcing by pharma companies, CDMOs are now focusing more on continuous bioprocessing and process intensification.
Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39117
There was unprecedented growth in 2020 due to the COVID-19 pandemic. The EFCG reported that around 80% of chemicals used to make drugs sold in Europe are supplied from India and China. The major factors fueling the growth of this market include increasing pharmaceutical R&D investment and the rising incidence of cancer and age-related disorders across the globe. Another factor fueling market growth is the growing demand for small molecule drugs. In 2020, small molecule drugs dominated new molecular entities (NMEs) approvals.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 73.9 billion by 2030 |
| Growth Rate | CAGR of 6.4% From 2022 to 2030 |
| Largest Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product, Stage type, Customer type, Therapeutic area |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Lonza Group Ltd.; Patheon; Cambrex Corporation; Catalent Inc.; Siegfried holdings AG; Recipharm AB; Corden Pharma International; Boehringer Ingelheim; Piramal Pharma Solutions; Covance Inc.; Wuxi AppTec ; Thermo Fisher Pantheon |
By Product Analysis
The small molecule API segment dominated the market and accounted for a revenue share of over 60.0% in 2021. This growth can primarily be attributed to the rising demand for small molecule innovators.
The small molecule drug product segment is expected to expand at a CAGR of 6.0% over the forecast period. The small molecule drug substances have become more complex, with manufacturing methods becoming more specialized.
By Stage Type Analysis
The clinical segment dominated the market in 2021 and held a revenue share of over 50.0%. The clinical phase represents the organization’s future, where mistakes can result in products not making it through the clinic or clinical programs being delayed, not to mention the impact on patients.
The commercial segment is projected to register the fastest growth rate of 7.2% over the forecast period. Rising demand for outsourcing by small- and medium-sized pharmaceutical companies is one of the factors driving the segment.
The labor paradigm that had previously serviced R&D activities will not work in the commercial space. This is where the role of CDMOs comes into play. CDMOs offer specialized expertise, time-saving, and cost-efficiency, which is likely to propel the segment growth during the forecast period.
By Customer Type Analysis
The pharmaceutical segment accounted for over 90.0% share of the global revenue in 2021. The biotechnology segment includes biotechnology firms. In these firms, the production of small molecules is also done.
The segment’s expansion is being fueled by factors such as rising biopharmaceutical demand and enhanced molecular efficiency. Furthermore, this growth can be attributed to large investments in the biotechnology and biopharmaceutical industries.
By Therapeutic Area Analysis
The oncology segment held the largest revenue share of over 40.0% in 2021 and is anticipated to register the fastest growth rate over the forecast period owing to the increasing number of cancer cases globally.
Increased government reimbursement policies and a rise in financing for the development of small molecule oncology therapies are other factors boosting the segment growth. In 2018, 42 NCEs were approved, and 38 in 2019 - a significant rise over the recent average of 25-35 NCE approvals per year.
The industry is also being driven by supportive government reimbursement policies and financing towards the development of small molecule oncology therapies. In addition, CDMOs are increasing their investments in facilities for the production of highly powerful APIs (HPAPIs).
By Regional Analysis
Asia Pacific accounted for the largest revenue share of over 40.0% in 2021. A key factor fueling the regional market growth is the significantly cheaper manufacturing costs than North America and Europe and favorable laws.
North America held the second-largest revenue share in 2021. It is one of the major contributors to the growth of the global market. It is characterized by the presence of several established pharmaceutical, biotechnology, and medical device companies.
Key Players
- Piramal Pharma Solutions
- Corden Pharma
- Wuxi AppTec
- Cambrex Corporation
- Recipharm AB
- Thermo Fisher Pantheon
- Lonza Group Ltd.
- Catalent Inc.
- Siegfried Holding AG
- Boehringer Ingelheim
- Covance Inc.
Market Segmentation
- By Product
- Small Molecule API
- Small Molecule Drug Product
- Oral Solid Dose
- Semi-Solid Dose
- Liquid Dose
- Others
- By Stage Type
- Preclinical
- Clinical
- Phase I
- Small
- Medium
- Large
- Phase II
- Small
- Medium
- Large
- Phase III
- Small
- Medium
- Large
- Phase I
- Commercial
- By Customer Type
- Pharmaceutical
- Small
- Medium
- Large
- Biotechnology
- Pharmaceutical
- By Therapeutic Area
- Cardiovascular Diseases
- Oncology
- Respiratory Disorders
- Neurology
- Metabolic Disorders
- Infectious Diseases
- Others
- Regional
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39117
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333